Related Experiment Video
Updated: Apr 10, 2026
09:28
Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents
Published on: September 16, 2020
9.6K
Anti-VEGF Therapy for Retinal Vein Occlusions
Claudio Campa1, Giuseppe Alivernini, Elena Bolletta
1Eye Clinic, S. Anna University Hospital - Ferrara, Italy. claudio.campa@yahoo.com.
Current Drug Targets
|June 16, 2015
Summary
Retinal vein occlusion (RVO) causes vision loss. Anti-vascular endothelial growth factor (VEGF) agents like ranibizumab, aflibercept, and bevacizumab are used to treat RVO, but optimal treatment regimens require further definition.
Area of Science:
- Ophthalmology
- Vascular Medicine
- Retinal Diseases
Background:
- Retinal vein occlusion (RVO) is a leading cause of vision impairment.
- Pathogenesis involves thrombus formation and vascular endothelial growth factor (VEGF) driven macular edema.
- Current treatments focus on anti-VEGF agents administered via intravitreal injections.
Purpose of the Study:
- To review the efficacy and safety of anti-VEGF agents for RVO.
- To compare the advantages and limitations of ranibizumab, aflibercept, and bevacizumab.
- To evaluate current treatment regimens for RVO.
Main Methods:
- Systematic review of MEDLINE database.
- Search terms included "retinal vein occlusion," specific anti-VEGF drugs, and "macular edema."
- Data extraction and verification by multiple authors.
Main Results:
- Ranibizumab, aflibercept, and bevacizumab are utilized for RVO treatment.
- Efficacy and safety data for these agents are under continuous evaluation.
- Optimal treatment frequency and duration remain undefined.
Conclusions:
- Anti-VEGF therapy is a cornerstone in managing RVO.
- Further research is needed to establish definitive treatment protocols.
- Comparative analysis of ranibizumab, aflibercept, and bevacizumab is crucial for clinical decision-making.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
01:28Angle Closure Glaucoma: Treatment
1.7K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.7K
01:26Varicose Veins II: Diagnostic Studies and Interprofessional Care
297
Varicose veins, or varicosities, develop when the valves in the veins, which control blood flow, weaken or damage. It causes blood to pool and the veins to enlarge. Understanding the clinical manifestations, diagnostic approaches, and management options for varicose veins is crucial for effective treatment and relief.Clinical manifestationsClinical manifestations of varicose veins include a heavy, achy feeling or pain after prolonged standing or sitting. This discomfort can often be relieved by...
297
01:24Regulation of Angiogenesis and Blood Supply
4.0K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
4.0K
01:29Venous Thrombosis III: Interprofessional Care
469
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
469